Mutations in the retinoblastoma (RB) tumour suppressor pathway are a hallmark of cancer and a prevalent feature of lung adenocarcinoma [1] [2] [3] . Although RB was the first tumour suppressor to be identified, the molecular and cellular basis that underlies selection for persistent RB loss in cancer remains unclear 4-6 . Methods that reactivate the RB pathway using inhibitors of cyclindependent kinases CDK4 and CDK6 are effective in some cancer types and are currently under evaluation for the treatment of lung adenocarcinoma 7-9 . Whether RB pathway reactivation will have therapeutic effects and whether targeting CDK4 and CDK6 is sufficient to reactivate RB pathway activity in lung cancer remains unknown. Here we model RB loss during lung adenocarcinoma progression and pathway reactivation in established oncogenic KRAS-driven tumours in mice. We show that RB loss enables cancer cells to bypass two distinct barriers during tumour progression. First, RB loss abrogates the requirement for amplification of the MAPK signal during malignant progression. We identify CDK2-dependent phosphorylation of RB as an effector of MAPK signalling and critical mediator of resistance to inhibition of CDK4 and CDK6. Second, RB inactivation deregulates the expression of cell-state-determining factors, facilitates lineage infidelity and accelerates the acquisition of metastatic competency. By contrast, reactivation of RB reprograms advanced tumours towards a less metastatic cell state, but is nevertheless unable to halt cancer cell proliferation and tumour growth due to adaptive rewiring of MAPK pathway signalling, which restores a CDK-dependent suppression of RB. Our study demonstrates the power of reversible gene perturbation approaches to identify molecular mechanisms of tumour progression, causal relationships between genes and the tumour suppressive programs that they control and critical determinants of successful cancer therapy.
. Fig. 2b ). Most KP lesions are slowly proliferating adenomas 8 weeks after tumour initiation, although a subset (around 15%) show early signs of carcinomatous progression that is marked by higher MAPK signalling and proliferation [11] [12] [13] [14] (Fig. 1d, e) . Notably, at this time more than 60% of KP;Rb TR/TR tumours were already carcinomas, had more proliferating cells and were larger than corresponding KP tumours ( tumours that were carcinomas was similar. However, despite a high rate of proliferation in both, KP carcinomas had high levels of p-MEK and p-ERK whereas KP;Rb TR/TR tumours did not ( Fig. 1d-i and Extended Data Fig. 3d ). Thus, although loss of RB strongly accelerates the transition to carcinoma, it largely abrogates the requirement for amplification of the MAPK signal to promote malignant progression.
RAS-dependent signalling induces expression of D-type cyclins that bind to CDK4 and CDK6 (hereafter CDK4/6), which phosphorylate RB to drive cells out of quiescence and promote G1 progression. The cyclin A/E-CDK2 complex subsequently hyperphosphorylates RB, which allows progression through the G1/S restriction point 15 . Thus, we determined the phosphorylation status of RB and ERK1/2 in mouse and human lung adenocarcinoma tissues. Tumours with predominantly p-ERK + cells also had high RB phosphorylation (p-RB), which correlated with progression to higher tumour grades ( Fig. 2a-d and Extended Data Fig. 3e-h ). Human tumours with undetectable expression of RB or p16 INK4A had lower p-ERK, similar to that observed in RB-deficient mouse tumours ( Fig. 2e and Extended Data Fig. 3e-h ). KP tumours that either naturally developed high levels of MAPK signalling or were pharmacologically induced to increase MAPK signalling, concurrently had high levels of p-ERK and p-RB S807/S811 (Extended Data Fig. 4a-c) . Additionally, these tumours had low p27, a negative regulator of CDK2, and high p-p27 T187, a CDK2-dependent modification that promotes p27 degradation [14] [15] [16] [17] [18] [19] [20] (Extended Data Fig. 4d-f ). Conversely, untreated KP;Rb TR/TR tumours and KP tumours treated with a MEK1/2 inhibitor had low levels of p-ERK, p-RB S807/S811 and p-p27 T187 and higher levels of total p27 (Extended Data Fig. 4c , g-k). These data suggest that amplification of MAPK signalling drives tumour progression by promoting CDK2-dependent suppression of RB.
Although current strategies to reactivate the RB pathway rely on inhibition of CDK4/6 in tumours in which Rb1 is intact, we found that palbociclib-a potent inhibitor of CDK4/6-had minimal effects on cell proliferation or colony formation of KP tumour-derived cells (Fig. 2f, g and Extended Data Fig. 5a ). By contrast, CDK2 inactivation alone significantly reduced proliferation and colony formation of KP Significance was calculated by two-sided χ 2 test. Number of tumours and P values are shown. n = 3 mice. c-e, Immunohistochemistry on human TMAs. c, p-ERK in RB-expressing tumours with low or high p-RB S807/S811. Tumour grade of (d) and p-ERK expression in (e) tumours in which the RB pathway is lost or intact. Significance was calculated by χ 2 test for trend. Number of samples is shown. f, Clonogenic growth of KP54 and KP62 cells with sgRNA against GFP or sgRNA against Cdk2, with or without palbociclib treatment. g, Area covered by cells using data from f. Data are mean ± s.d. Significance was determined by analysis of variance (ANOVA) with Sidak's correction for multiple comparisons. n = 2 biological replicates, n = 3 technical replicates. P values were calculated from technical replicates. h, Clonogenic growth of human cell lines with non-genome targeting (hereafter inert) sgRNA or sgRNA against CDK2 , with or without palbociclib treatment. i, Area covered by cells using data from h. Data are mean ± s.d. Significance was determined by ANOVA with Sidak's correction for multiple comparisons. n = 3 technical replicates. j, Xenograft growth of A549 (top) and H838 (bottom) cells that express inert or CDK2-targeting sgRNAs. The day on which palpable masses had formed was set to day 0 and on this day treatments were initiated (t = 0). Data are mean ± s.d. Tumour volume significance was determined by unpaired two-tailed Student's t-test on day 16. Number of mice is shown. Combination of CDK2 sgRNA and palbociclib treatment is synergistic (A549 and H838 cells, combination index = 0.274 and 0.000002237, respectively). requirement for RB suppression leads to a compensatory increase in CDK4/6-dependent RB suppression and a de novo vulnerability to inhibition of CDK4/6.
Many human lung adenocarcinoma cell lines are refractory to CDK4/6 inhibition despite expressing wild-type RB 21 (Extended Data  Fig. 5j ). To determine whether loss of CDK2 activity sensitizes human lung adenocarcinoma cells to CDK4/6 inhibition, we inactivated CDK2 using CRISPR in four human RB1 wild-type lines (Extended Data  Fig. 5k ). In A549 and EKVX cells-which are sensitive to the CDK4/6 inhibitor-loss of CDK2 further decreased growth after palbociclib treatment (Fig. 2h-j and Extended Data Fig. 5l, m) . Similar to KP cells, in H838 and H1993 cells-which are relatively resistant to palbociclib-CDK2 loss created de novo sensitivity to CDK4/6 inhibition ( Fig. 2h-j and Extended Data Fig. 5l, m) . These data suggest that CDK2-specific inhibitors may be a potential additional therapeutic option that would synergize with existing CDK4/6-targeted therapies to more potently reactivate the RB pathway and suppress tumour growth.
Progression of lung adenocarcinoma is marked by a worsening of nuclear pleomorphism (grades 3 and 4) and the presence of desmoplasia and transition to a poorly differentiated phenotype (grade 5) 11, 12 . At 14 weeks after tumour initiation, when more advanced tumours are likely to occur, KP carcinomas were primarily grade 3 and 4, whereas a significant fraction of KP;Rb TR/TR carcinomas were already grade 5 lesions (Fig. 3a) . Notably, around 40% of KP;Rb TR/TR mice also had widespread metastases to local lymph nodes and/or the pleural cavity. No metastases were observed in KP mice at this time point (Fig. 3a and Extended Data Fig. 6a ). Within human lung adenocarcinoma datasets 1, 22 , RB pathway deficiency did not affect tumour stage, which is a measure of size and position (Fig. 3b) . However, patients whose tumours had RB pathway alterations were significantly more likely to have metastases and higher grade tumours, indicating a preponderance of poorly differentiated disease (Fig. 3b, c) . Before gaining metastatic ability, KP tumours silence the lineage-specifying transcription factors NKX2-1 and FOXA2, and derepress HMGA2, a metastasis-associated, chromatin-regulating factor the expression of which is normally restricted to embryonic cell types 23, 24 (Fig. 3d , e and Extended Data Fig. 6b ). However, KP;Rb TR/TR tumours and metastases frequently co-expressed HMGA2, NKX2-1 and FOXA2 (Fig. 3d , e and Extended Data Fig. 6b-d) . Moreover, derepression of HMGA2 was frequent in grade 3 KP;Rb TR/TR carcinomas that expressed NKX2-1 (Fig. 3d, f) . Although no KP;Rb TR/TR tumours expressed club cell or neuroendocrine markers, a subset lost the surfactant protein C (SPC) lineage marker despite maintaining NKX2-1 and a well-differentiated morphology; a pattern that was not observed in KP tumours (Fig. 3d, g ). Therefore, RB deficiency subverts lineage fidelity and promotes alternative pathways to gain metastatic ability.
On the basis of the expression of NKX2-1 and HMGA2, KP cell lines can be classified into those that are derived from tumours that lacked a metastatic ability (NKX2-1 
HMGA2
+ KP cell lines did not (Extended Data Fig. 7a,  b) . Primary metastatic tumours and extra-pulmonary metastases that were sorted directly from KP lesions also had fewer p16
INK4A
-specific transcripts than non-metastatic tumours 25 (Extended Data Fig. 7c, d Letter reSeArCH Data Fig. 7f-i) . Thus, the RB pathway has a critical role constraining the acquisition of metastatic competency.
The Rb1 XTR allele allowed us to model therapeutic reactivation of the RB pathway in lung tumours that were growing within their autochthonous environment by crossing a Rosa26
FlpO-ER allele into the KP;Rb XTR/XTR mouse line
26
. Twelve weeks after tumour initiation, we administered tamoxifen to activate FlpO-ER and restore RB expression (Rb R/R ) ( Fig. 4a, b) . Although we observed only a small decrease in the average rate of tumour growth, Rb1 reactivation significantly extended overall survival by more than 4 weeks and was indistinguishable from mice that had KP tumours that expressed RB throughout the course of tumour development ( Fig. 4c and Extended Data Fig. 8a-d) . Thus, the tumour-suppressive effects of Rb1 reactivation-although therapeutic-can be blunted, possibly by similar mechanisms active in KP tumours. We also performed immunohistochemistry and determined the grades of KP;Rb TR/TR and KP;Rb R/R tumours, 3, 7, and 14 days after Rb1 reactivation. Although RB expression was heterogeneous early after Rb1 reactivation, by 14 days RB expression was homogeneous in KP;Rb R/R tumours (Fig. 4d , e and Extended Data Fig. 8d ). KP;Rb R/R tumours had significantly reduced proliferation indicated by less Ki67 staining than KP;Rb TR/TR tumours 3 days after Rb1 reactivation; however, this equilibrated to a level that was only modestly less than KP;Rb TR/TR tumours (Extended Data Fig. 9a-c) . Notably, the number of tumours with predominant p-ERK and p-RB S807/S811 staining progressively increased after Rb1 reactivation (Fig. 4d-f and Extended Data Fig. 9d ). In contrast to the transient effect on proliferation, Rb1 reactivation had a progressive effect on the histological state of KP;Rb R/R tumours. HMGA2 expression became increasingly less frequent and less likely to be co-expressed with NKX2-1, and NKX2-1 and SPC expression became more frequent (Fig. 4d, e and Extended Data Fig. 9e ). Whereas, KP;Rb TR/TR tumours were predominately grade 4 and some grade 5 lesions, KP;Rb R/R tumours reverted towards lower grades-most tumours were either grade 2 or 3-and a markedly reduced number of metastases was present 14 days after Rb1 reactivation (Fig. 4g, h ). Thus, reinstating RB pathway activity in advanced tumours only transiently represses cell proliferation due to an adaptive rewiring of the MAPK signalling pathway. However, RB progressively reprograms tumours towards less aggressive cell states that are unlikely to metastasize.
RB is a pleiotropic tumour suppressor with canonical roles that respond to mitogenic cues and regulate cell cycle progression, as well as multiple less well understood non-canonical roles that regulate plasticity of cellular states 5, 6 . Our study uncovers RB suppression as a major effect of oncogenic MAPK signal transduction during early carcinoma progression, and highlights the role of RB in maintaining lineage commitment as a critical barrier to the development of metastatic disease (Extended Data Fig. 10a, b) . We identified CDK2 as an effector of the MAPK signalling pathway and determinant of the success of cancer therapies that are aimed at reactivating the RB pathway, reinforcing the need for potent and selective CDK2 inhibitors 27 (Extended Data Fig. 10c-f) . Finally, our data reveal that therapies that aim to reactivate the RB pathway may have tumour-suppressive effects, not by suppressing cell proliferation, but instead by reverting cell state changes associated with advanced tumour progression.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1172-9. . The acquisition of μCT was performed on μCT setup (MI Labs) with Acquisition 7.45 software. Image reconstruction and visualization was performed with MI Labs REC-7.09. Individual tumour volumes were determined by constructing three-dimensional tomograms within MicroView v.2.5 (Parallax Innovations). Lentivirus production and titration was performed as described previously 29 . Rodent Laboratory Diet (AIN-76A) was formulated with PLX4720 at 417 mg kg −1 or PD0325901 at 7 mg kg −1 by Research Diets. For Rb1 restoration, mice were treated with tamoxifen on two consecutive days with 200 μl of a 20 mg ml −1 solution dissolved in 90% sterile corn oil and 10% ethanol by oral gavage. BrdU incorporation was performed by injecting mice at 30 mg kg −1 (Sigma-Aldrich, B5002) into the peritoneal cavity 16-24 h before necropsy. Mice in survival studies were monitored for lethargy, laboured breathing and weight loss, at which time animals were euthanized. No statistical methods were used to predetermine sample sizes. The size of each animal cohort was determined by estimating biologically relevant effect sizes between control and treated groups and then using the minimum number of animals that could reveal statistical significance using the indicated tests of significance. All animal studies were randomized in 'control' or 'treated' groups. However, all animals housed within the same cage were generally placed within the same treatment group. For histopathological assessments of tumour grades, researchers were blinded to sample identity and group. Animal sex was randomized at the time of treatment group assignment. CRISPR design and production. sgRNAs that target the second exon of mouse Cdk2 and human CDK2 were designed using the optimized CRISPR design tool (crispr.mit.edu). sgRNA duplexes were Golden Gate-cloned into BsmBI sites of the LentiCRISPRv2Puro vector to produce inert, and GFP-and Cdk2-targeting lentivirus [29] [30] [31] . The sgRNAs used for targeting Cas9 are: GFP GGGCGAGGAGCTGTTCACCG 31 , inert GCTTGAGCACATACGCGAAT 32 and Cdk2/CDK2 GATCTCTCGGATGGCAGTAC, which targets both mouse Cdk2 and human CDK2. 
Immunohistochemistry and immunofluorescence. Lung and tumour tissues
were dissected into 10% neutral-buffered formalin overnight at room temperature before dehydration in a graded alcohol series. Paraffin-embedded and H&E -stained histological sections were produced at the Abramson Family Cancer Research Institute Histopathology Core. Human lung tissue microarrays were assembled and provided by C.D. and purchased from US Biomax (LC706a). Immunostaining for both mouse tissue and human tissue microarrays was performed after citrate-based antigen retrieval with antibodies targeting GFP (Cell Signaling, 2956), phosphorylated MEK1/2 (Cell Signaling, cs2338), phosphorylated ERK1/2 (Cell Signaling, cs4370), BrdU (BD Transduction Laboratories, 347580), Ki67 (Vector Laboratories, VP-RM04), NKX2-1 (Abcam, ab76013), HMGA2 (Biocheck, 59170AP), FOXA2 (Cell Signaling, 8186), SPC (Millipore, AB3786), CC10 (Santa Cruz, sc-9772), p-RB S807/S811 (Cell Signaling, cs8516), p27 (BD Biosciences, 610241), p-p27 S10 (Abcam, ab62364), p-p27 T187 (Abcam, ab75908). RB (Abcam, ab181616) immunostaining was performed after EDTA (pH 8.0)-based antigen retrieval. Immunostaining for p16 was performed by the Pathology Clinical Service Center at the Hospital of the University of Pennsylvania. ABC reagent (Vector Laboratories, PK-4001) and ImmPACT DAB (Vector Laboratories, SK-4105) were prepared and used according to the product instructions. Immunofluorescence was performed on the paraffin-embedded sections following the same antigen-retrieval protocol. Sections were incubated in primary antibody for 16-20 h at 4 °C and then exposed to fluorescent secondary detection (Invitrogen; anti-rabbit Alexa594 (A21207) and anti-mouse Alexa647 (A31571)) for 1 h at room temperature in the dark. Photomicrographs were captured on a Leica DMI6000B inverted light and fluorescence microscope.
Histological quantification. ImageJ software was used to determine the percentage of lung area occupied by the tumour on H&E-stained slides, and the frequency of cells that were positive for specified antigens as a fraction of total tumour cells. Data points represent individual mice for tumour burden graphs and individual tumours for BrdU, Ki67, p-MEK, p-ERK and p-RB S807/S811 by immunohistochemistry. Histological quantification of mouse tumours was performed by quantifying the frequency of cells that were positive and then scoring high and low as follows: For Ki67 and p-RB S807/S811: low, <10% positive cells per tumour; high, ≥10% positive cells per tumour. For p-ERK, NKX2-1, HMGA2, SPC and RB: low, <30% positive cells per tumour; high, ≥30% positive cells per tumour. For p27, p-p27 S10 and p-p27 T187, staining score for each tumour was determined based on staining intensity scored from 0 (no staining) to 3 (very dark staining). For comparisons of p-ERK and p27, p-p27 S10 and p-p27 T187, p-ERK-low tumours were defined as <30% positive cells per tumour and p-ERK-high tumours were defined as ≥70% positive cells per tumour. PennVet Comparative Pathology Core determined individual mouse tumour grades by using established tumour-grading schemes in experiments 12, 33 . Histological quantification of human tissue microarrays was performed by quantifying the frequency of cells that were positive and the staining intensity for RB, p16, p-ERK and p-RB S807/S811. RB + and p16 + tumours were both defined as those with greater than 20% of cells having medium or strong staining intensity, and the Rb pathway was designated as intact if the tumour was positive for both RB and p16. p-RB S807/S811-high tumours were defined as those containing greater than 10% positive cells. p-ERK staining was scored on a four-point scale with score 0 indicating no staining, score 1 indicating either low staining or less than 20% of cells with medium or high staining, score 2 indicating medium staining in greater than 20% of cells, and score 3 indicating high staining in greater than 20% of cells.
In vivo metastasis models. KP and KP;Rb TR/TR cells were subcutaneously implanted in the lower right flank of B6129PF1/J mice (Jax stock number 100492) at 5 × 10 4 cells per inoculum. Mice were euthanized 6 weeks after inoculation. Primary tumour, lung, liver and kidney tissues were collected and processed for histology. Mice were visually examined for macroscopic metastatic tumours and lung metastases were quantified from H&E-stained sections. For the intrasplenic injection model of metastasis, B6129PF1/J mice were anaesthetized with isoflurane. The left subcostal area was shaved, then prepared with 70% ethanol and iodine. A small incision was made in line with the left ear through the peritoneum. Through the excision, the exposed spleen was divided by placing a microvascular clip down the centre. Tumour cells were injected at a concentration of 1 × 10 5 in a 50-μl volume of PBS. After 10 min, a microvascular clip was placed on the downstream vasculature at the injection site and then the spleen was removed. Mice were euthanized after 4 weeks and macroscopic liver metastases were counted. During the experimental time course, subcutaneous tumours never grew above 1.0 cm 3 and mice with liver tumours were never under duress (that is, with a body condition less than 2) during the experiment. Laser capture microdissection. Laser capture microdissection was performed on 4-μm paraffin-embedded histological sections, mounted on membrane slides (Molecular Machines & Industries, 50102). Tumour cells were captured using a Nikon Eclipse TE2000-S onto isolation caps (Molecular Machines & Industries, 50202). DNA was isolated from samples according to the guidelines in the PicoPure DNA Extraction Kit (Thermo Fisher Scientific, KIT0103). DNA was used as template for quantitative PCR to measure the conversion of Rb TR to Rb R by amplifying the GFP portion of the Rb TR allele. The reaction was normalized to Gapdh and compared to standardized DNA ratios of Rb TR and Rb R alleles. Primers used: GFP forward 5′-GACGTAAACGGCCACAAGTT-3′ and reverse 5′-GAACTTCAGGGTCAGCTTGC-3′; Gapdh forward 5′-TGTCCGTCGTGGAT CTGAC-3′ and reverse 5′-CCTGCTTCACCACCTTCTTG-3′. Cell lines. Mouse cell lines were generated from primary mouse tumours and propagated using standard techniques. Human lung adenocarcinoma cell lines were obtained from ATCC or NIH Cell line repository. HEK293FT cells that were used for lentivirus production were obtained from Invitrogen. GreenGo cells used for lentivirus titration were obtained from the laboratory of T. Jacks and are a derivative of NIH3T3 cells. Mouse cell lines were authenticated for genotype. Human and mouse lung cancer cell lines were tested for the expected, genotype-associated protein expression patterns by western blot. HEK293FT cells that were used for lentivirus production were validated by verifying that high-titre virus production was possible. NIH3T3-GreenGo cells were validated by measuring Cre-induced GFP expression. All human cell lines tested negative for mycoplasma as performed by the cell line repository or manufacturer. Mouse cell lines were not tested. Human lung adenocarcinoma cell lines H2009 and A549 were grown in F12K medium and H838, EKVX and H1993 cells were grown in RPMI. Mouse cell lines were derived from individual lung tumours from Kras ) mice. In brief, tumours were excised from the lungs of mice, dissociated with trypsin for 60 min and then quenched with fetal bovine serum. Digested tumours were passed through a 40-μm cell strainer and cultured in high-glucose DMEM supplemented with 10% fetal bovine serum, GlutaMAX and antibiotics at 37 °C and 5% CO 2 until cell line establishment. Proliferation of cell lines was determined by plating the indicated cell number and analysed by manual cell counts using a haemocytometer at the indicated time points. Cell cycle analysis was performed according to the manufacturer's instructions for the APC BrdU Flow Kit (BD Pharmingen). Clonogenic survival assays were performed by plating 500 cells per well in a six-well plate. After approximately 16 h, cells were treated with DMSO or palbociclib (Selleck Chemicals) at the indicated doses every 3 days for 1.5 or 3.5 weeks. Cells were then fixed by incubating in ice-cold methanol for 10 min and then stained with crystal violet dye for 15 min. Plates were imaged and the relative area covered by cell colonies was determined with ImageJ software. Immunoblot analysis. KP and KP;Rb TR/TR cells were lysed in RIPA buffer, resolved on NuPage 4-12% Bis-Tris protein gels (Thermo Fisher) and transferred to polyvinylidene fluoride (PVDF) membranes. Blocking, primary and secondary antibody incubations were performed in Tris-buffered saline (TBS) with 0.1% Tween-20. Total ERK1/2 (Cell Signaling, cs4696), CDK2 (Abcam, ab32147), CDK4 (Abcam, ab199728), CDK6 (Abcam, ab151247), β-actin (Sigma Aldrich, A2066), HSP90 (BD Transduction Laboratories, 610418), p-RB S780 (Cell Signaling, 9307), p16 (Abcam, ab211542) and cyclin D1 (Abcam, ab16663) were assessed by western blotting. HSP90 and β-actin were used as loading control. All other antibodies are the same as indicated for immunohistochemistry. RNA sequencing and human dataset analysis. For RNA sequencing, RNA was isolated from 4 KP and 4 KP;Rb TR/TR lung tumour-derived cell lines using the RNeasy Mini Kit (Qiagen) as per the manufacturer's instructions. RNA concentrations were measured using the Qubit RNA HS Assay Kit (Invitrogen) and sample quality was determined using the RNA 6000 Nano Kit on a 2100 BioAnalzyer (Agilent). Sequencing libraries were prepared using the TruSeq Stranded mRNA Library Prep Kit (Illumina) as per the manufacturer's instructions and subjected to 75-bp paired-end sequencing on the Illumina NextSeq 500 platform. Fastq files for each sample were aligned against the mouse genome, build GRCm38.p4, using the STAR aligner (v.2.5.2b) 34 . featureCounts (v.1.5.0-p1) was used to quantify alignments against the mouse genomic annotations from Gencode (v.M11) 35 . Differentially expressed genes were identified with DESeq2 (v.1.14.0) 36 and an 'Rb signature' gene signature was defined as genes with a false-discovery rate adjusted P value less than 0.05 and log 2 -normalized fold change in expression greater than ±0.8 (46 genes were downregulated and 63 genes were upregulated in KP;Rb TR/TR cells). Single-sample gene set enrichment analysis (ssGSEA) was performed at https://genepattern.broadinstitute.org/gp/ using the ssGSEAProjection module 37 . Provisional TCGA lung adenocarcinoma z-score mRNA-expression data extracted from CBioPortal was used as the input expression dataset and the Rb signature gene signature was used as the gene set 38 . Rb signature high samples were defined as those with an enrichment score greater than 1,000; Rb signaturelow samples were defined as those with an enrichment score less than −1,000. Kaplan-Meier analysis was performed to examine the differential survival of the Rb signature high samples and Rb signature low samples. MSK-IMPACT-NSCLC survival analysis was performed by Kaplan-Meier analysis using data from CBioPortal 3, 38 . Rb pathway alterations were defined as mutations or copy number alterations in RB1, CDKN2A, CDK2, CDK4, CDK6, CCND1 or CCNE1. For ONCOMINE-based analyses of tumour stage, lymph node metastasis, distant metastasis, tumour grade and tumour size, loss of the Rb pathway was defined as a loss of one or more copies of RB1 or CDKN2A, or a gain of one or more copies of CDK2, CDK4, CDK6, CCND1 or CCNE1 1, 2, 39 . For analysis of p16:Arf ratios in mouse tumours and metastases, RNA sequencing data were downloaded from GEO (accession number GSE84447) 25 using the SRA Toolkit and aligned against the mouse genome, build GRCm38.p6, using the STAR aligner (v.2.5.2b). BAM files were indexed using samtools (v.1.9) and read counts at Cdkn2a exon 1α (p16) and exon 1β (Arf) were quantified using Integrative Genomics Viewer (v.2.4.10). Outliers were defined as greater than Q3 + 1.5× interquartile range or less than Q1 − 1.5× interquartile range and excluded. Sashimi plots were generated using Integrative Genomics Viewer (v.2.4.10), as were read counts from the Cdkn2a locus for NKX2-1 −
HMGA2
+ and NKX2-1 + HMGA2 − cell lines. Statistics and reproducibility. All analyses were performed in the Graphpad Prism (v.7.0a) software package. For tumour burden, BrdU, Ki67, p-ERK, p-MEK, p27, p-p27 S10 and p-p27 T187, ratio of p16:Arf reads and human tumour size, unpaired Student's t-tests were performed. For tumour grade distribution, human tumour stage distribution and p-ERK staining in relation to Rb pathway status and p-RB S807/S811 staining, contingency analyses with a χ 2 test for trend was used. Other contingency analyses used a standard χ 2 test. A log-rank (Mantel-Cox) test was performed to determine significance in survival studies. Compusyn software (ComboSyn) was used to evaluate synergism between inhibition of CDK4/6 and CRISPR-mediated knockout of CDK2, whereby a Combination Index score less than 1 indicates synergy 40 . For Fig. 1c, d , experiments were repeated 5 times each for mice at 8 weeks and 9 and 12 times for KP and KP;Rb TR/TR mice at 14 weeks, respectively, with similar results. For Fig. 2a , the experiment was repeated 3 times on separate mice, with similar results. For Fig. 3d, Data Fig. 2b, c , the experiments were repeated twice, with similar results. For Extended Data Fig. 3a , the experiment was repeated 5 times each for KP and KP;Rb TR/TR mice. For Extended Data Fig. 3b , the experiment was repeated twice for 8-week time points, and 3 times for 14-week time points. For Extended Data Fig. 3e -h, all staining experiments were repeated twice, with similar results. For Extended Data Fig. 4a , the experiment was repeated 4 times for control-treated mice and 5 times for PLX4720-treated mice. For Extended Data Fig. 4j , the experiment was repeated twice for control mice and 3 times for PD035901-treated mice. For Extended Data Fig. 5i , l, the experiments were repeated twice with similar results. For Extended Data Fig. 5k , the experiment was repeated more than 5 times with similar results. For Extended Data Fig. 6a-d , the experiment was repeated 5 times on separate mice. For Extended Data Fig. 6e , the experiment was repeated 3 times on separate mice. For Extended Data Fig. 7a , e, the experiments were repeated 3 times each with similar results. For Extended Data Fig. 7h , the experiment was repeated 3 or more times for each cell line. For Extended Data Fig. 8b , c, the experiment was repeated 6 times each for KP;Rb TR/TR and KP;Rb R/R mice. For Extended Data Fig. 9a , the experiment was repeated 3 times for each time point. For Extended Data Fig. 9d , the experiment was repeated twice for each time point. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All data generated or analysed during this study are included in this published Letter (and its Supplementary Information) with the exception of raw RNA sequencing data associated with Extended Data Fig. 2e , f, which have been deposited publicly in the Gene Expression Omnibus (GEO) under accession number GSE128506. Source Data associated with Figs. 1e-i, 2b-e, g, i, j, 3a-c, e-g, 4c, e-h and Extended Data Figs. 2d-f, 3c, d, 4b , d-i, k, 5a-h, j, m, 6c, d, 7d, f, g, i, 8a, d, 9b, c, e are available in the online version of the paper. Raw images from western blots are shown in Supplementary Fig. 1 . In gels with multiple bands per lane or in which specific lanes were selected, the locations at which gels were cropped are also shown. For Extended Data Figs. 2b, c, 5i , k, 7e, controls were run on separate gels as sample-processing controls; for Extended Data Fig. 7a , loading controls for each gel are provided in the Supplementary Information. Fig. 1 | The RB pathway is frequently altered in human lung adenocarcinoma. a, Oncoprint from CBioPortal showing frequency and co-occurrence of mutations and copy number alterations in RB pathway components, KRAS and TP53 in the provisional lung adenocarcinoma TCGA dataset 38 . b, RB pathway components and their corresponding mutation frequencies in the provisional lung adenocarcinoma TCGA dataset. c, Kaplan-Meier survival analysis of patients with lung adenocarcinoma whose tumours do (n = 456 patients) or do not (n = 987 patients) contain alterations in RB pathway members. Patient data were obtained from the MSK-IMPACT clinical sequencing cohort. Significance was determined by two-sided log-rank test (P = 0.0015). Source Data can be found at the cBioPortal 38 .
Extended Data
Letter reSeArCH TR/TR (n = 4) cell lines. The RB signature, defined by genes for which the change in expression is ≥2-fold and the P value adjusted for multiple testing is ≤ 0.05, is boxed. Statistical significance was determined by two-sided Wald's test using BenjaminiHochberg correction using DESeq2. f, Kaplan-Meier survival analysis of patients with lung adenocarcinoma whose tumours exhibit a high (n = 114 patients) or low (n = 189 patients) Rb signature. Significance was determined by two-sided log-rank test. P = 0.0175. nature research | reporting summary All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample sizes. The size of each animal cohort was determined by estimating biologically relevant effect sizes between control and treated groups and then using the minimum number of animals that could reveal statistical significance using the indicated tests of significance.
Data exclusions In analysis of Cdkn2a reads from RNA-Seq datasets, outliers were excluded based on pre-established criteria (greater than Q3 + 1.5x
interquartile range or less than Q1 -1.5x interquartile range). No other data were excluded from analyses Replication
Cell culture experiments described were repeated with at least 3 independent replicates and on at least two separate occasions with significant results in the same direction as those represented in the figures. Independent experiments (or experimental groups) were combined as indicated and when appropriate (e.g. when multiple cell lines with the same genotype had the same phenotype).
Randomization All animal studies were randomized in 'Control' or 'Treated' groups. However, all animals housed within the same cage were generally placed within the same treatment group.
Blinding
For analysis of tumour grades sample identity and group identity were blinded from histopathological assessment.
Reporting for specific materials, systems and methods 
Validation
When possible, antibodies were validated beyond the manufacturers data sheet specification by staining slides (IHC) or blots (western) with known deficiencies for expression of the antigen.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s)
Murine cell lines were generated from primary mouse tumors and propagated using standard techniques. Human lung adenocarcinoma cell lines were obtained from ATCC or NIH Cell line repository. HEK293FT cells used for lentivirus production were obtained from Invitrogen. GreenGo cells used for titering lentivirus were obtained from Tyler Jack's Laboratory and are a derivative of NIH3T3 cells.
Authentication
Mouse cell lines were authenticated for genotype. Human and mouse lung cancer cell lines were tested for the expected, genotype-associated protein expression patterns by western blot. HEK293FT cells used for lentivirus production were validated by verifying high titter virus production was possible. NIH3T3-GreenGo cells were validated by measuring Creinduced GFP expression.
Mycoplasma contamination
Human cells were tested negative by the cell line repository or the manufacturer. Mouse cell lines were not tested.
Commonly misidentified lines (See ICLAC register)
We have not used any commonly misidentified cell lines in this study.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Cells were isolated from culture dishes using trypsin-EDTA, washed 3x with PBS and fixed according to the APC BrdU Flow Kit (BD Pharmingen).
Instrument
Attune acoustic focusing cytometer
Software
FlowJo v10
Cell population abundance Greater than 20,000 total events/cells were acquired.
Gating strategy
All events were separated based on APC and 7-AAD staining and gated as shown. BrdU negative cells were used to establish thresholds for gates. Clear separtaion between G1 and G2/M populations were established by assuming that G2/M cells would be twice as bright for 7-AAD than G1 cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
